Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484219 | 1.00 | PREP (0.49) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL6475389 | 1.00 | PREP (0.49) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL3637452 | 0.97 | FKBP1A (0.48) | PREPACE2 | |
| SCHEMBL29560191 | 0.93 | SMN1; SMN2 (0.45) | PREP | |
| SCHEMBL3638539 | 0.89 | ACE2 (0.48) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL31153718 | 0.88 | TSHR (0.46) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL3806981 | 0.86 | PREP (0.47) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL30781570 | 0.85 | POLB (0.44) | PREP | |
| SCHEMBL29012380 | 0.84 | PREP (0.50) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL34466974 | 0.84 | PREP (0.42) | PREPACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939891-B2 | Nitrogen compounds such as N-(4-Fluorophenyl)-N'-[(R)-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea, used as analgesics | SMITHKLINE BEECHAM, PLC (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| US-5637731-A | CHOLINERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-10 | — | — | US | disclosed |
| US-5550257-A | TREATING CENTRAL CHOLINERGIC DYSFUNCTION | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5451685-A | MANUFACTURING PHARMACEUTICALS | AMERICAN CYANAMID COMPANY (US) | 1995-09-19 | — | — | US | disclosed |
| US-5356885-A | Cholinergic agents; administering for treatment of diseases of the central nervous system | AMERICAN CYANAMID COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0510333-A1 | Substituted oxotremorine derivatives | AMERICAN CYANAMID COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | TRPV1, UTS2R, GPR17 | PREP 1657/4885ACE2 1089/4885NPSR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.